Patents by Inventor Francisco Borrás Cuesta
Francisco Borrás Cuesta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140056943Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.Type: ApplicationFiled: September 27, 2013Publication date: February 27, 2014Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Aintzane ZABALETA AZPIROZ, Francisco BORRAS CUESTA, Jesus PRIETO VALTUENA, Pablo SAROBE UGARRIZA, Juan Jose LASARTE SAGASTIBELZA
-
Patent number: 8524860Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.Type: GrantFiled: November 14, 2008Date of Patent: September 3, 2013Assignee: Proyecto de Biomedicina CIMA, S.L.Inventors: Inés Noelia Casares Lagar, Francisco Borrás Cuesta, Pablo Sarobe Ugarriza, Jesús Maria Prieto Valtueña, Juan José Lasarte Sagastibelza
-
Publication number: 20130064790Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: ApplicationFiled: March 8, 2012Publication date: March 14, 2013Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Lorea MANTEROLA CAREAGA, Inés Noelia CASARES LAGAR, Nancy Díaz-Valdés Farray, Javier DOTOR DE LAS HERRERÍAS, Juan José LASARTE SAGASTIBELZA, Pablo SAROBE UGARRIZA, Jesús PRIETO VALTUEÑA, Francisco BORRÁS CUESTA
-
Patent number: 8158589Abstract: The described peptides possess the capacity to bind to Transforming Growth Factor TGF-?1 (TGF-?1), and are potential inhibitors of the biological activity of TGF-?1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-?1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze.Type: GrantFiled: February 22, 2010Date of Patent: April 17, 2012Assignees: Proyecto Biomedicine Cima, S.L., Digna Biotech, S.L.Inventors: Javier Dotor Herrerías, Francisco Borrás Cuesta, Esperanza Feijoo Blanco
-
Patent number: 8148334Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: GrantFiled: March 27, 2008Date of Patent: April 3, 2012Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Lorea Manterola Careaga, Inés Noelia Casares Lagar, Nancy Díaz-Valdés Farray, Javier Dotor de las Herrerías, Juan José Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesús Prieto Valtueñ, Francisco Borrás Cuesta
-
Publication number: 20110268757Abstract: The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSM?, PSM? and PSM? peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo.Type: ApplicationFiled: December 2, 2009Publication date: November 3, 2011Applicants: INSTITUT PASTEUR, PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Francisco Borrás Cuesta, Inés Noelia Casares Lagar, María del Carmen Durántez Delgado, Juan José Lasarte Sagastibelza, Claude Leclerc, Jesús María Prieto Valtueña, Pablo Sarobe Ugarriza
-
Publication number: 20100267623Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.Type: ApplicationFiled: November 14, 2008Publication date: October 21, 2010Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Inés Noelia Casares Lagar, Francisco Borras Cuesta, Pablo Sarobe Ugarriza, Jesús Prieto Valtueña, Juan José Lasarte Sagastibelza
-
Publication number: 20100222280Abstract: The described peptides possess the capacity to bind to Transforming Growth Factor TGF-?1 (TGF-?1), and are potential inhibitors of the biological activity of TGF-?1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-?1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze.Type: ApplicationFiled: February 22, 2010Publication date: September 2, 2010Inventors: JAVIER DOTOR HERRERÍAS, ANA BELÉN LÓPEZ VÁZQUEZ, JUAN JOSÉ LASARTE SAGASTIBELZA, JESÚS PRIETO VALTUEÑA, FRANCISCO BORRÁS CUESTA, ESPERANZA FEIJOO BLANCO
-
Publication number: 20100168015Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: ApplicationFiled: March 27, 2008Publication date: July 1, 2010Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Lorea Manterola Careaga, Inés Noelia Casares Lagar, Nancy Diaz-Valdés Farray, Javier Dotor De Las Herrerias, Juan José Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesús Prieto Valtueña, Francisco Borràs Cuesta
-
Publication number: 20100047231Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.Type: ApplicationFiled: October 5, 2006Publication date: February 25, 2010Inventors: Aintzane Zabaleta Azpiroz, Francisco Borras Cuesta, Jesus Prieto Valtuena, Pablo Sarobe Ugarriza, Juan Jose Lasarte Sagastibelza
-
Patent number: 7666841Abstract: The described peptides possess the capacity to bind to Transforming Growth Factor TGF-?1 (TGF-?1), and are potential inhibitors of the biological activity of TGF-?1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-?1 expression.Type: GrantFiled: July 5, 2004Date of Patent: February 23, 2010Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Javier Dotor De Las Herrerías, Ana Belen Lopez Vazquez, Juan Jose Lasarte Sagastibelza, Jesus Prieto Valtuena, Francisco Borras Cuesta
-
Publication number: 20090263410Abstract: The present invention relates to the use of a peptide inhibiting TGF-?1 selected from: peptide p144 whose sequence corresponds to SEQ ID NO: 1, peptide p17 whose sequence corresponds to SEQ ID NO: 2, a peptide which has at least 90% homology therewith, or fragments of the above, in the preparation of an immune response modulating agent.Type: ApplicationFiled: October 24, 2005Publication date: October 22, 2009Applicant: Proyecto De Biomedicina Cima, S.L.Inventors: Francisco Borras Cuesta, Noelia Casares Agar, Javier Dotor De Las Herrerias, Lucia Gil Guerrero, Juan Jose Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesus Prieto Valtuena
-
Publication number: 20090220533Abstract: The invention relates to a chimeric peptide, which can bind to at least one allelic form of the HLA-DR molecule. The invention also relates to a pharmaceutical composition containing said peptide, as well as to the different uses of same.Type: ApplicationFiled: December 19, 2006Publication date: September 3, 2009Inventors: Francisco Borras Cuesta, Juan Jose Lasarte Sagastibelza, Marta Ruiz Egozcue, Pablo Sarobe Ugarriza
-
Patent number: 7582609Abstract: A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-?, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-?, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.Type: GrantFiled: March 1, 2006Date of Patent: September 1, 2009Assignee: Digna Biotech, S.L.Inventors: Francisco Borras Cuesta, Javier Dotor De Las Herrerias, Juan Manuel Irache Garreta, Fernando Martinez Galan, Jesus Prieto Valtuena
-
Patent number: 7528226Abstract: Antagonistic synthetic peptides, obtained from TGF?1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.Type: GrantFiled: April 11, 2006Date of Patent: May 5, 2009Assignee: Rojecto de Biomedicina Cima S.L.Inventors: Ignacio José Ezquerro Saenz, Juan José Lasarte Sagastibelza, Jesús Prieto Valtueña, Francisco Borras Cuesta
-
Publication number: 20070207965Abstract: A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-?, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-?, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.Type: ApplicationFiled: March 1, 2006Publication date: September 6, 2007Inventors: Francisco Borras Cuesta, Javier Dotor De Las Herrerias, Juan Manuel Irache Garreta, Fernando Martinez Galan, Jesus Prieto Valtuena
-
Publication number: 20070014767Abstract: Antagonistic synthetic peptides, obtained from TGF?1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.Type: ApplicationFiled: April 11, 2006Publication date: January 18, 2007Inventors: Ignacio Ezquerro Saenz, Juan Lasarte Sagastibelza, Jesus Prieto Valtuena, Francisco Borras Cuesta
-
Patent number: 7057013Abstract: Antagonistic synthetic peptides, obtained from TGF?1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.Type: GrantFiled: November 23, 1999Date of Patent: June 6, 2006Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Ignacio José Ezquerro Saenz, Juan José Lasarte Sagastibelza, Jesús Prieto Valtue{overscore (n)}a, Francisco Borras Cuesta